iCasp9 anti-ROR1 CAR-T cells

iCasp9 anti-ROR1 CAR-T cells is a preclinical chimeric antigen receptor (CAR) T-cell therapy designed to target receptor tyrosine kinase-like orphan receptor 1 (ROR1). ROR1 is a tumor-associated antigen overexpressed in various hematological malignancies, such as mantle cell lymphoma (MCL) and multiple myeloma, as well as solid tumors. To mitigate the risks of severe treatment-related toxicities like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the CAR-T cells are engineered to co-express an inducible caspase 9 (iCasp9) suicide gene safety switch. Upon administration of a small-molecule dimerizer (such as AP1903/rimiducid), the iCasp9 system is activated, rapidly triggering apoptosis and selective elimination of the CAR-T cells. This therapeutic candidate is being preclinically developed by researchers at the Iuliu Hațieganu University of Medicine and Pharmacy.

Other names

anti-ROR1 CAR T cells incorporating the iCasp9 safety switchanti-ROR-1 CAR T cells incorporating the iCasp9 safety switchanti-ROR 1 CAR T cells incorporating the iCasp9 safety switchiCasp9 transfected anti-ROR1 CAR-T cellsiCasp-9 transfected anti-ROR1 CAR-T cellsiCasp 9 transfected anti-ROR1 CAR-T cellsiCasp9-transduced anti-ROR1 CAR-T cellsiCasp-9-transduced anti-ROR1 CAR-T cellsiCasp 9-transduced anti-ROR1 CAR-T cells